Indaptus Therapeutics, Inc. (NASDAQ: INDP) is a Healthcare company (Biotechnology) with a market capitalization of $359M. The Maz Rating grades it against the other companies in its sector.
About three months ago (July 2, 2026), Indaptus Therapeutics, Inc. had a Maz Rating of 2.40 out of 5 (C, Hold), ranked against the other companies in its sector. Its strongest factor then was Valuation (4.15), more attractively valued than most of its sector; its weakest was Profitability (1.09), among the weakest in its sector. The other factors: Financial Health 3.45 (around the middle of its sector); Momentum 3.18 (around the middle of its sector); Growth 1.74 (below most of its sector). The current rating is for members: log in to see it.
At $3.17, Indaptus Therapeutics, Inc. trades at 32.2x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -302.8%, return on invested capital of -129.9% and a free cash flow yield of -4.3%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 19.48. Over the past 52 weeks the share price ranged from $0.92 to $5.96, with a beta of 1.17.
Indaptus Therapeutics, Inc. does not currently pay a dividend.
2 Wall Street analyst ratings cover the stock: 2 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.